Zhang Xiaojie, Huang Hao, Han Lu, Li Tiepeng, Wang Zibing, Gao Quanli
Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Front Oncol. 2021 May 28;11:640447. doi: 10.3389/fonc.2021.640447. eCollection 2021.
Treatment with a combination of programmed cell death-1 (PD-1) blocker and cytokine-induced killer (CIK) cells has improved outcome in cancer patients but is also associated with various patterns of responses. Pseudoprogression is a unique and uncommon phenomenon with no clear criteria for rapid diagnosis. Although some reports of pseudoprogression during immunotherapy exist, there are few reports of pseudoprogression occurring twice in the same patient. Here, we report the case of 51-year-old female patient with advanced renal cell carcinoma, who received a combination treatment of PD-1 blocker and CIK cells, and where pseudoprogression of lung and brain tumors occurred successively during treatment.
程序性细胞死亡蛋白1（PD-1）阻断剂与细胞因子诱导的杀伤细胞（CIK）联合治疗已改善了癌症患者的预后，但也与多种反应模式相关。假性进展是一种独特且罕见的现象，目前尚无快速诊断的明确标准。尽管已有一些关于免疫治疗期间假性进展的报道，但同一患者出现两次假性进展的报道却很少。在此，我们报告一例51岁晚期肾细胞癌女性患者，该患者接受了PD-1阻断剂与CIK细胞的联合治疗，治疗期间肺和脑肿瘤相继出现假性进展。
